WhiteLab Genomics develops a proprietary platform that leverages graph knowledge technology and machine learning to help companies discover and design new genomic therapies to face challenges such as optimizing payload, vector design, assessing genotoxicity, and identifying optimal experimental protocols for in vivo and in vitro strategies. WhiteLab Genomics guides its clients through the in-silico development phases to provide patients with access to new genomic therapies.